CPA
CRSP icon

Capital Performance Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Capital Performance Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-42
Closed -$1.97K – 745
2024
Q3 		$1.97K Buy
+42
New +$2.13K ﹤0.01% 1570

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Performance Advisors's CRSP Position: Q4 2024 in Review

Capital Performance Advisors sold out of CRISPR Therapeutics (CRSP) in Q4 2024, closing a stake of 42 shares — an estimated $1.97K sold.

Capital Performance Advisors first reported a position in CRSP in Q3 2024 and held it in 1 quarter. The position peaked at $1.97K in Q3 2024. 404 funds tracked by Wall St. Rank hold CRSP as of Q4 2024.

  • Capital Performance Advisors reported no remaining CRISPR Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 42 CRISPR Therapeutics shares in Q4 2024, an estimated $1.97K.
  • Capital Performance Advisors first reported a position in CRISPR Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's CRISPR Therapeutics position peaked at $1.97K in Q3 2024.
  • 404 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.